![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JM Gimble, CE Robinson, X Wu, KA Kelly, BR Rodriguez, SA Kliewer, JM Lehmann and DC Morris
Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA.
The thiazolidinediones improve insulin sensitivity in animal models and have promise as potent oral antidiabetic agents. Their clinical use has been limited because of the resulting anemia and cardiac hypertrophy. Some compounds of this class have been reported to induce bone marrow fat accumulation in animals, and this effect could account for the observed anemia. We examined the biological mechanism contributing to this phenomenon. The thiazolidinediones BRL49653 and pioglitazone induced adipocyte differentiation in the BMS2 bone marrow stromal cell line in a dose- and time-dependent manner. These actions were further enhanced by the presence of glucocorticoids and other adipogenic agonists. The thiazolidinediones increased the mRNA levels of adipocyte- specific genes, including that of their receptor, the peroxisome proliferator-activated receptor-gamma (PPAR gamma). In contrast, mRNA levels of genes encoding other PPAR family members (PPAR alpha, PPAR delta, or NUC-1) were unchanged or decreased. Thiazolidinedione treatment of primary bone marrow stromal cells elicited a comparable dose-dependent response. Using a polyclonal antibody, PPAR gamma was detected in protein lysates from adipose-rich bone marrow. Thus, thiazolidinedione directly regulates bone marrow stromal cell differentiation; induced PPAR gamma expression may play a key regulatory role in this process.
This article has been cited by other articles:
|
|
 |
|
  K. Y. Chung and B. J. Johnson Application of cellular mechanisms to growth and development of food producing animals J Anim Sci, April 1, 2008; 86(14_suppl): E226 - E235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhang, N. Yang, and X.-M. Shi Regulation of Mesenchymal Stem Cell Osteogenic Differentiation by Glucocorticoid-induced Leucine Zipper (GILZ) J. Biol. Chem., February 22, 2008; 283(8): 4723 - 4729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. David, A. Martin, M.-H. Lafage-Proust, L. Malaval, S. Peyroche, D. B. Jones, L. Vico, and A. Guignandon Mechanical Loading Down-Regulates Peroxisome Proliferator-Activated Receptor {gamma} in Bone Marrow Stromal Cells and Favors Osteoblastogenesis at the Expense of Adipogenesis Endocrinology, May 1, 2007; 148(5): 2553 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Duque As a Matter of Fat: New Perspectives on the Understanding of Age-Related Bone Loss IBMS BoneKEy, April 1, 2007; 4(4): 129 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Grey, M. Bolland, G. Gamble, D. Wattie, A. Horne, J. Davidson, and I. R. Reid The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1305 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Falconi, K. Oizumi, and J. E. Aubin Leukemia Inhibitory Factor Influences the Fate Choice of Mesenchymal Progenitor Cells Stem Cells, February 1, 2007; 25(2): 305 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Desvergne, L. Michalik, and W. Wahli Transcriptional Regulation of Metabolism Physiol Rev, April 1, 2006; 86(2): 465 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sastre, I. Dewachter, S. Rossner, N. Bogdanovic, E. Rosen, P. Borghgraef, B. O. Evert, L. Dumitrescu-Ozimek, D. R. Thal, G. Landreth, et al. Nonsteroidal anti-inflammatory drugs repress {beta}-secretase gene promoter activity by the activation of PPAR{gamma} PNAS, January 10, 2006; 103(2): 443 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Klotz, M. Schmidt, T. Giese, M. Sastre, P. Knolle, T. Klockgether, and M. T. Heneka Proinflammatory Stimulation and Pioglitazone Treatment Regulate Peroxisome Proliferator-Activated Receptor {gamma} Levels in Peripheral Blood Mononuclear Cells from Healthy Controls and Multiple Sclerosis Patients J. Immunol., October 15, 2005; 175(8): 4948 - 4955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A. Soroceanu, D. Miao, X.-Y. Bai, H. Su, D. Goltzman, and A. C Karaplis Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J. Endocrinol., October 1, 2004; 183(1): 203 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rieusset, J. Seydoux, S. I. Anghel, P. Escher, L. Michalik, N. Soon Tan, D. Metzger, P. Chambon, W. Wahli, and B. Desvergne Altered Growth in Male Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Heterozygous Mice: Involvement of PPAR{gamma} in a Negative Feedback Regulation of Growth Hormone Action Mol. Endocrinol., October 1, 2004; 18(10): 2363 - 2377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Desvergne, L. Michalik, and W. Wahli Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the Road Mol. Endocrinol., June 1, 2004; 18(6): 1321 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Ogilvie, R. Saladin, T. R. Nagy, M. S. Urcan, R. A. Heyman, and M. D. Leibowitz Activation of the Retinoid X Receptor Suppresses Appetite in the Rat Endocrinology, February 1, 2004; 145(2): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O. Rzonca, L. J. Suva, D. Gaddy, D. C. Montague, and B. Lecka-Czernik Bone Is a Target for the Antidiabetic Compound Rosiglitazone Endocrinology, January 1, 2004; 145(1): 401 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rieusset, F. Touri, L. Michalik, P. Escher, B. Desvergne, E. Niesor, and W. Wahli A New Selective Peroxisome Proliferator-Activated Receptor {gamma} Antagonist with Antiobesity and Antidiabetic Activity Mol. Endocrinol., November 1, 2002; 16(11): 2628 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J D Tugwood and C T Montague Biology and toxicology of PPARg ligands Human and Experimental Toxicology, August 1, 2002; 21(8): 429 - 437. [Abstract] [PDF]
|
|
|
|
|
|
G. K. Chan, R. A. Deckelbaum, I. Bolivar, D. Goltzman, and A. C. Karaplis PTHrP Inhibits Adipocyte Differentiation by Down-Regulating PPAR{gamma} Activity via a MAPK-Dependent Pathway Endocrinology, November 1, 2001; 142(11): 4900 - 4909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. ROSSMEISL, I. SYROVY, F. BAUMRUK, P. FLACHS, P. JANOVSKÁ, and J. KOPECKY Decreased fatty acid synthesis due to mitochondrial uncoupling in adipose tissue FASEB J, September 1, 2000; 14(12): 1793 - 1800. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. J. Cox, D. A. Ryan, F. J. Hollis, A.-M. Harris, A. K. Miller, M. Vousden, and H. Cowley Absorption, Disposition, and Metabolism of Rosiglitazone, a Potent Thiazolidinedione Insulin Sensitizer, in Humans Drug Metab. Dispos., July 1, 2000; 28(7): 772 - 780. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. D. Pennie, J. D. Tugwood, G. J. A. Oliver, and I. Kimber The Principles and Practice of Toxicogenomics: Applications and Opportunities Toxicol. Sci., April 1, 2000; 54(2): 277 - 283. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Butler, S. H. Mitchell, D. J. Tindall, and C. Y. F. Young Nonapoptotic Cell Death Associated with S-Phase Arrest of Prostate Cancer Cells via the Peroxisome Proliferator-activated Receptor {{gamma}} Ligand, 15-Deoxy-{{Delta}}12,14- prostaglandin J2 Cell Growth Differ., January 1, 2000; 11(1): 49 - 61. [Abstract] [Full Text]
|
|
|
|
|
|
R. Okazaki, M. Toriumi, S. Fukumoto, M. Miyamoto, T. Fujita, K. Tanaka, and Y. Takeuchi Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro Endocrinology, November 1, 1999; 140(11): 5060 - 5065. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. C. M. Tsibris, K. B. Porter, A. Jazayeri, G. Tzimas, H. Nau, H. Huang, K. Kuparadze, G. W. Porter, W. F. O'Brien, and W. N. Spellacy Human Uterine Leiomyomata Express Higher Levels of Peroxisome Proliferator-activated Receptor {{gamma}}, Retinoid X Receptor {{alpha}}, and all-trans Retinoic Acid Than Myometrium Cancer Res., November 1, 1999; 59(22): 5737 - 5744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Desvergne and W. Wahli Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism Endocr. Rev., October 1, 1999; 20(5): 649 - 688. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. R. Hill, S. Clarke, K. Rodgers, B. Thornhill, J. M. Peters, F. J. Gonzalez, and J. M. Gimble Effect of Peroxisome Proliferator-Activated Receptor Alpha Activators on Tumor Necrosis Factor Expression in Mice during Endotoxemia Infect. Immun., July 1, 1999; 67(7): 3488 - 3493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Johnson, R. Vogel, S. J. Rutledge, G. Rodan, and A. Schmidt Thiazolidinedione Effects on Glucocorticoid Receptor-Mediated Gene Transcription and Differentiation in Osteoblastic Cells Endocrinology, July 1, 1999; 140(7): 3245 - 3254. [Abstract] [Full Text]
|
|
|
|
|
|
C. E. Robinson, X. Wu, Z. Nawaz, S. A. Onãte, and J. M. Gimble A Corepressor and Chicken Ovalbumin Upstream Promoter Transcriptional Factor Proteins Modulate Peroxisome Proliferator-Activated Receptor-{gamma}2/Retinoid X Receptor {alpha}-Activated Transcription from the Murine Lipoprotein Lipase Promoter Endocrinology, April 1, 1999; 140(4): 1586 - 1593. [Abstract] [Full Text]
|
|
|
|
|
|
J. Berger, M. D. Leibowitz, T. W. Doebber, A. Elbrecht, B. Zhang, G. Zhou, C. Biswas, C. A. Cullinan, N. S. Hayes, Y. Li, et al. Novel Peroxisome Proliferator-activated Receptor (PPAR) gamma and PPARdelta Ligands Produce Distinct Biological Effects J. Biol. Chem., March 5, 1999; 274(10): 6718 - 6725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Burris, P. D. Pelton, L. Zhou, M. C. Osborne, E. Cryan, and K. T. Demarest A Novel Method for Analysis of Nuclear Receptor Function at Natural Promoters: Peroxisome Proliferator-Activated Receptor {gamma} Agonist Actions on aP2 Gene Expression Detected Using Branched DNA Messenger RNA Quantitation Mol. Endocrinol., March 1, 1999; 13(3): 410 - 417. [Abstract] [Full Text]
|
|
|
|
 |
|
 J Gros, C. Gerhardt, and A. Strosberg Expression of human (beta)3-adrenergic receptor induces adipocyte-like features in CHO/K1 fibroblasts J. Cell Sci., January 11, 1999; 112(21): 3791 - 3797. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Baillie, X. Sha, P. Thuillier, and S. D. Clarke A novel 3T3-L1 preadipocyte variant that expresses PPAR{gamma}2 and RXR{alpha} but does not undergo differentiation J. Lipid Res., October 1, 1998; 39(10): 2048 - 2053. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. R. Bauer, M. J. Ruiz-Hidalgo, E. K. Rudikoff, J. Goldstein, and J. Laborda Modulated Expression of the Epidermal Growth Factor-Like Homeotic Protein dlk Influences Stromal-Cell-Pre-B-Cell Interactions, Stromal Cell Adipogenesis, and Pre-B-Cell Interleukin-7 Requirements Mol. Cell. Biol., September 1, 1998; 18(9): 5247 - 5255. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. W. Robinson, P. F. Johnson, L. Hennighausen, and E. Sterneck The C/EBPbeta transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland Genes & Dev., June 15, 1998; 12(12): 1907 - 1916. [Abstract] [Full Text]
|
|
|
|
|
|
K. A. Kelly and J. M. Gimble 1,25-Dihydroxy Vitamin D3 Inhibits Adipocyte Differentiation and Gene Expression in Murine Bone Marrow Stromal Cell Clones and Primary Cultures Endocrinology, May 1, 1998; 139(5): 2622 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Kelly, S. Tanaka, R. Baron, and J. M. Gimble Murine Bone Marrow Stromally Derived BMS2 Adipocytes Support Differentiation and Function of Osteoclast-Like Cells in Vitro Endocrinology, April 1, 1998; 139(4): 2092 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-Z. Su, M. Wang, D. L. Oxender, and A. R. Saltiel Troglitazone Increases System A Amino Acid Transport in 3T3-L1 Cells Endocrinology, March 1, 1998; 139(3): 832 - 837. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
